Short Interest in Dermata Therapeutics, Inc. (NASDAQ:DRMA) Increases By 141.3%

Dermata Therapeutics, Inc. (NASDAQ:DRMA) was the target of a significant increase in short interest in July. As of July 15th, there was short interest totalling 52,600 shares, an increase of 141.3% from the June 30th total of 21,800 shares. Based on an average trading volume of 1,080,000 shares, the short-interest ratio is currently 0.0 days. Approximately 8.1% of the company’s stock are short sold.

Dermata Therapeutics Stock Down 6.2 %

NASDAQ:DRMA traded down $0.16 on Friday, hitting $2.42. The stock had a trading volume of 213,020 shares, compared to its average volume of 533,659. Dermata Therapeutics has a 52 week low of $1.29 and a 52 week high of $23.10. The business’s fifty day moving average is $2.78 and its 200 day moving average is $5.03. The company has a market cap of $1.36 million, a PE ratio of -0.09 and a beta of 0.75.

Dermata Therapeutics (NASDAQ:DRMA) last posted its earnings results on Wednesday, May 15th. The company reported ($7.05) earnings per share for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Dermata Therapeutics stock. Armistice Capital LLC bought a new stake in Dermata Therapeutics, Inc. (NASDAQ:DRMA) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 218,000 shares of the company’s stock, valued at approximately $133,000. Armistice Capital LLC owned approximately 6.16% of Dermata Therapeutics as of its most recent SEC filing. 8.67% of the stock is currently owned by institutional investors and hedge funds.

Dermata Therapeutics Company Profile

Dermata Therapeutics, Inc, a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea.